• Je něco špatně v tomto záznamu ?

Identification and structure elucidation of a new degradation impurity in the multi-component tablets of amlodipine besylate

P. Gibala, M. Douša, A. Kalužíková, M. Tkadlecová, M. Štefko, S. Kalášek, J. Břicháč,

. 2019 ; 162 (-) : 112-116. [pub] 20180726

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012352

New unknown impurity at m/z 421.15 was observed during the accelerated stability analysis (40 °C/75% relative humidity) in the multi-component tablets of amlodipine besylate by reversed-phase ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS). UHPLC-MS and nuclear magnetic resonance (NMR) techniques were employed to identify and fully characterize the degradation compound. The degradation product was unambiguously identified as 3-ethyl 5-methyl 4-(2-chlorophenyl)-6-methyl-2-(morpholin-2-yl)-1,4-dihydropyridine-3,5-dicarboxylate and mechanism of its formation was proposed. It was confirmed that the degradation product was formed by the reaction of amlodipine with formaldehyde originating from the excipients present in the dosage form.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012352
003      
CZ-PrNML
005      
20190405092755.0
007      
ta
008      
190405s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jpba.2018.07.040 $2 doi
035    __
$a (PubMed)30236818
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gibala, Petr $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
245    10
$a Identification and structure elucidation of a new degradation impurity in the multi-component tablets of amlodipine besylate / $c P. Gibala, M. Douša, A. Kalužíková, M. Tkadlecová, M. Štefko, S. Kalášek, J. Břicháč,
520    9_
$a New unknown impurity at m/z 421.15 was observed during the accelerated stability analysis (40 °C/75% relative humidity) in the multi-component tablets of amlodipine besylate by reversed-phase ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS). UHPLC-MS and nuclear magnetic resonance (NMR) techniques were employed to identify and fully characterize the degradation compound. The degradation product was unambiguously identified as 3-ethyl 5-methyl 4-(2-chlorophenyl)-6-methyl-2-(morpholin-2-yl)-1,4-dihydropyridine-3,5-dicarboxylate and mechanism of its formation was proposed. It was confirmed that the degradation product was formed by the reaction of amlodipine with formaldehyde originating from the excipients present in the dosage form.
650    _2
$a amlodipin $x chemie $7 D017311
650    _2
$a farmaceutická chemie $x metody $7 D002626
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a chromatografie s reverzní fází $7 D056148
650    _2
$a fixní kombinace léků $7 D004338
650    12
$a kontaminace léku $7 D004340
650    _2
$a stabilita léku $7 D004355
650    _2
$a pomocné látky $x chemie $7 D005079
650    _2
$a formaldehyd $x chemie $7 D005557
650    _2
$a hydrochlorthiazid $x chemie $7 D006852
650    _2
$a magnetická rezonanční spektroskopie $7 D009682
650    _2
$a molekulární struktura $7 D015394
650    _2
$a hmotnostní spektrometrie s elektrosprejovou ionizací $7 D021241
650    _2
$a časové faktory $7 D013997
650    _2
$a valsartan $x chemie $7 D000068756
655    _2
$a časopisecké články $7 D016428
700    1_
$a Douša, Michal $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic. Electronic address: michal.dousa@seznam.cz.
700    1_
$a Kalužíková, Aneta $u Department of Analytical Chemistry, Faculty of Science, Charles University in Prague, Hlavova 2030/8, CZ-128 43 Prague 2, Czech Republic; The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, CZ-166 10 Prague 6, Czech Republic.
700    1_
$a Tkadlecová, Marcela $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
700    1_
$a Štefko, Martin $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
700    1_
$a Kalášek, Stanislav $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
700    1_
$a Břicháč, Jiří $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
773    0_
$w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 162, č. - (2019), s. 112-116
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30236818 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190405092805 $b ABA008
999    __
$a ok $b bmc $g 1391662 $s 1050657
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 162 $c - $d 112-116 $e 20180726 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...